Revenue
2022
2023
2024
2025
Citius Oncology, Inc. (CTOR)
Price$0.8600Cached quote
Net income
2021
2022
2022
2023
2023
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2022
2022
2023
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 · Dec 31 | 2023 · Sep 30 | 2022 | 2022 | 2021 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $0 | — | $0 | — |
| Research & development | $6.4M | $4.9M | — | $4.2M | — | $3.4M | — |
| Operating expenses | $23.5M | $20.6M | — | $12.1M | — | $4.9M | — |
| Operating income | −$23.5M | −$20.6M | −$1.0M | −$12.1M | −$138,115 | −$4.9M | −$10,113 |
| EBITDA | −$23.5M | −$20.6M | — | −$12.1M | — | −$4.9M | — |
| Net income | −$24.8M | −$21.1M | $2.4M | −$12.7M | $380,811 | −$5.4M | −$10,113 |
| Basic EPSper basic share | -$0.34 | -$0.31 | $0.27 | -$0.19 | $0.12 | -$0.08 | -$0.01 |
| Diluted EPSper diluted share | -$0.34 | -$0.31 | $0.27 | -$0.19 | $0.12 | -$0.08 | — |
Owners
Reported shareholders
≈62.05%of listed shares
Citius Pharmaceuticals, Inc.65.63M shares · Aug 12, 2024
View holders
| Holder | % owned |
|---|---|
Citius Pharmaceuticals, Inc. | ≈62.05%65.63M shares |
ARMISTICE CAPITAL, LLC | 8.23%8.71M shares |
BANK OF AMERICA CORP /DE/ | 3.63%3.84M shares |
Mazur Leonard L | ≈1.61%1.7M shares |
HOLUBIAK MYRON Z | ≈0.80%850K shares |
Bartushak Jaime | ≈0.78%825K shares |
Czuczman Myron | ≈0.78%825K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.52%546.33K shares |
UBS Group AG | 0.32%334.62K shares |
Mayersohn Joel David | ≈0.30%321.23K shares |
MCGRATH DENNIS M | ≈0.28%300K shares |
Dutia Suren G | ≈0.28%300K shares |
Webb Carol | ≈0.28%300K shares |
Holuka Eugene Myron | ≈0.28%300K shares |
Smith Robert Joseph | ≈0.28%300K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.23%245.41K shares |
VANGUARD FIDUCIARY TRUST CO | 0.12%121.91K shares |
IFP Advisors, Inc | 0.10%107.42K shares |
CITADEL ADVISORS LLC | 0.09%90.59K shares |
NORTHERN TRUST CORP | 0.04%45.75K shares |
Percentages use 105.76M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data